| Literature DB >> 17318340 |
Liselotte P van Hest1, Mariëlle W G Ruijs, Anja Wagner, Conny A van der Meer, Senno Verhoef, Laura J van't Veer, Hanne Meijers-Heijboer.
Abstract
Li-Fraumeni syndrome (LFS) is an autosomal dominantly inherited cancer predisposition syndrome characterized by a combination of tumors including sarcoma, breast cancer, brain tumors, adrenocortical carcinoma and leukemia. Germline mutations in the tumor suppressor gene TP53 are associated with LFS. We present a family with LFS in which initially a novel germline TP53 intron 5 splice site mutation was found. A second germline TP53 mutation, the exon 7 Asn235Ser (704A-->G) mutation, was detected in this family through pre-symptomatic DNA testing. This latter mutation has been reported repeatedly in the literature as a pathogenic mutation involved in LFS. We provide evidence for pathogenicity of the novel intron 5 splice site mutation, whereas this evidence is lacking for the exon 7 Asn235Ser (704A-->G) mutation. Our findings emphasize the importance of performing additional tests in case of germline sequence variants with uncertain functional effects.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17318340 DOI: 10.1007/s10689-006-9115-7
Source DB: PubMed Journal: Fam Cancer ISSN: 1389-9600 Impact factor: 2.375